Drug Type Bispecific antibody |
Synonyms Briakinumab (USAN/INN), Ozespa, A-796874.0 + [8] |
Target |
Action inhibitors |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors), Immunosuppressants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09588 | Briakinumab |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | NDA/BLA | United States | - | |
Plaque psoriasis | NDA/BLA | European Union | - | |
Psoriasis | NDA/BLA | - | - | |
Psoriasis | NDA/BLA | - | - | |
Crohn Disease | Phase 2 | United States | 01 Nov 2007 | |
Crohn Disease | Phase 2 | Australia | 01 Nov 2007 | |
Crohn Disease | Phase 2 | Austria | 01 Nov 2007 | |
Crohn Disease | Phase 2 | Belgium | 01 Nov 2007 | |
Crohn Disease | Phase 2 | Canada | 01 Nov 2007 | |
Crohn Disease | Phase 2 | Denmark | 01 Nov 2007 |
Phase 3 | 317 | Briakinumab | kouqsmlbth(msmueaydgp) = cnhqsilbzl aelqdjnvhn (uqmfwyreaj ) | Positive | 27 Oct 2011 | ||
Methotrexate | kouqsmlbth(msmueaydgp) = zifcugrhiz aelqdjnvhn (uqmfwyreaj ) | ||||||
Phase 2 | 215 | tfcywejxzb(bkasgjmpya) = Although rates of adverse events were not significantly different between ABT-874 treatment groups and placebo, the magnitude of ABT-874 efficacy was less than that observed with other agents currently in development for MS treatment prlfvhpzcs (nngeocdjgn ) | Negative | 01 Feb 2011 | |||
Placebo | |||||||
NCT00292396 (Pubmed) Manual | Phase 2 | 180 | ABT-874 one 200-mg dose at week 0 | ctrejmiirx(liciffvoka) = zonzundpvq svuscfgjyv (ajbuvyhquf ) | Positive | 01 Feb 2008 | |
ABT-874 100 mg every other week for 12 weeks | ctrejmiirx(liciffvoka) = tszzflvgbb svuscfgjyv (ajbuvyhquf ) |